Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | F2R | P25116 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585802 | 0.82 | KMT2A (0.37) | ALDH1A1KDM4EHPGDCYP1A2KMT2A | |
| SCHEMBL2251037 | 0.79 | NPC1 (0.39) | KDM4EKMT2AMAPTNPC1RAB9A | |
| SCHEMBL2251554 | 0.79 | SCN9A (0.40) | ALDH1A1L3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL845034 | 0.77 | GBA1 (0.43) | ALDH1A1KDM4EKMT2ASMN1; SMN2MAPT | |
| SCHEMBL3228237 | 0.76 | ALDH1A1 (0.38) | ALDH1A1KDM4ECYP1A2L3MBTL1SMN1; SMN2 | |
| SCHEMBL28557994 | 0.75 | GAA (0.45) | ALDH1A1KDM4EHPGDPOLBGLA | |
| SCHEMBL2251909 | 0.74 | SMN1; SMN2 (0.43) | ALDH1A1HPGDCYP1A2SMN1; SMN2MAPT | |
| SCHEMBL3596324 | 0.74 | SMN1; SMN2 (0.39) | ALDH1A1HPGDPOLBKMT2AL3MBTL1 | |
| SCHEMBL11188970 | 0.74 | USP2 (0.40) | ALDH1A1KDM4EHPGDCYP1A2KMT2A | |
| SCHEMBL2255369 | 0.72 | CYP1A2 (0.44) | ALDH1A1KDM4ECYP1A2POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558360-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | ALFASIGMA S.P.A. (IT) | 2026-02-24 | — | — | US | disclosed |
| US-20250289816-A1 | SALTS AND PHARMACUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ALFASIGMA S.P.A. (IT) | 2025-09-18 | — | — | US | disclosed |
| US-12234235-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | ALFASIGMA S.P.A. (IT) | 2025-02-25 | — | — | US | disclosed |
| US-20240325405-A1 | COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2024-10-03 | — | — | US | disclosed |
| US-12042498-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | ALFASIGMA S.P.A. (IT) | 2024-07-23 | — | — | US | disclosed |
| US-20230406857-A1 | SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ALFASIGMA S.P.A. (IT) | 2023-12-21 | — | — | US | disclosed |
| EP-3283114-B1 | METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | GALAPAGOS NV (BE) | 2023-09-06 | — | — | EP | disclosed |
| US-11667633-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2023-06-06 | — | — | US | disclosed |
| US-20210369727-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2021-12-02 | — | — | US | disclosed |
| EP-3842432-A1 | NOVEL SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2021-06-30 | — | — | EP | disclosed |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| WO-2010133318-A1 | METHODS FOR THE IDENTIFICATION OF PHOSPHATIDYLINOSITOL KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF PHOSPHATIDYLINOSITOL KINASE PROTEINS | CELLZOME AG (DE) | 2010-11-25 | — | — | WO | disclosed |
| EP-2222674-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | Cellzome Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| EP-2217578-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-08-18 | — | — | EP | disclosed |
| US-20100029709-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010191-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES. | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010187-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009068482-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009047514-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325405-A1 | COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, BMP6, JAK1 | ALDH1A1 2388/4885KDM4E 3137/4885HPGD 1688/4885 |
| US-12558360-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | JAK1, IL6, STAT3 | ALDH1A1 679/4885KDM4E 3107/4885HPGD 2363/4885 |
| US-20100029709-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TRAF6, IL6, TLR6 | ALDH1A1 2773/4885KDM4E 2087/4885HPGD 1089/4885 |
| US-11667633-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL6, JAK1, COL1A1 | ALDH1A1 360/4885KDM4E 4333/4885HPGD 1711/4885 |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | ALDH1A1 2831/4885KDM4E 1582/4885HPGD 3521/4885 |
| US-12234235-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL6, JAK1, COL1A1 | ALDH1A1 360/4885KDM4E 4333/4885HPGD 1711/4885 |
| US-12042498-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | IL6, JAK1, BMP6 | ALDH1A1 1465/4885KDM4E 3095/4885HPGD 1286/4885 |
| US-20250289816-A1 | SALTS AND PHARMACUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL6, JAK1, BMP6 | ALDH1A1 315/4885KDM4E 4629/4885HPGD 1288/4885 |
| US-20210369727-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | ALDH1A1 2497/4885KDM4E 2923/4885HPGD 2167/4885 |
| US-20230406857-A1 | SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL6, JAK1, COL1A1 | ALDH1A1 360/4885KDM4E 4333/4885HPGD 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.